Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Instituto Nacional de Estadística. Defunciones según la causa de muerte.
Instituto Nacional de Estadística, editor. Estadísticas del movimiento natural de la población. Año 1995,
[2.]
J. Díez, C. Laviades.
Los retos de la hipertensión arterial en el siglo XXI.
Nefrología, 19 (1999), pp. 487-491
[4.]
R.E. Pratt, V.J. Dzau.
Genomics and hypertension. Concepts, potentials, and opportunities.
Hypertension, 33 (1999), pp. 238-247
[5.]
C.A. Hughes, V. Bennett.
Adducin: a physical model with implications for function in assembly of spectrin-actin complexes.
J Biol Chem, 270 (1995), pp. 18990-18996
[6.]
G. Bianchi, G. Tripodi, G. Casari.
Two point mutations within the adducin genes are involved in blood pressure variation.
Proc Natl Acad Sci USA, 91 (1994), pp. 3999-4003
[7.]
G. Casari, C. Barlassina, D. Cusi.
Association of the a-adducin locus with essential hypertension.
Hypertension, 25 (1995), pp. 320-326
[8.]
D. Cusi, C. Barlassina, T. Azzani, G. Casari, L. Citterio, M. Devoto.
Polymorphism of a-adducin and salt sensitivity in patients with essential hypertension.
Lancet, 349 (1997), pp. 1353-1357
[9.]
B. Rigat, C. Hubert, F. Alhenc-Gelas, F. Cambien, P. Corvol, F. Soubrier.
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.
J Clin Invest, 86 (1990), pp. 1343-1346
[10.]
O. Costerousse, J. Allegrini, M. López, F. Alhenc-Gelas.
Angiotensin I-converting enzyme in the human circulating mononuclear cells: genetic polymorphism of expression in T lymphocytes.
Biochem J, 290 (1993), pp. 33-40
[11.]
K. Kario, N. Kanai, S. Nishima, T. Fujii, K. Saito, T. Matsuo.
Hypertensive nephropathy and the gene for angiotensin-converting enzyme.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 252-256
[12.]
P. Fernández-Llama, E. Poch, J. Oriola, A. Botey, E. Coll, A. Darnell.
Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis.
Kidney Int, 53 (1998), pp. 1743-1747
[13.]
J.L. Rodicio.
Does antihypertensive therapy protect the kidney in essential hypertension?.
J Hypertens, 14 (1996), pp. 69-75
[14.]
W.B. Kannel, J.B. Stokes.
III. Hypertension as a cardiovascular risk factor.
Handbook of hypertension, pp. 15-34
[15.]
B.M. Massie, N.B. Shah.
The heart failure epidemic: magnitude of the problem and potential mitigating approaches.
Curr Opin Cardiol, 11 (1996), pp. 221-226
[16.]
F. Valderrábano, F. Gómez-Campderá, E.H.P. Jones.
Hypertension as cause of end-stage renal disease: lessons from international registries.
Kidney Int, 54 (1998), pp. 60-66
[17.]
F. Forette, F. Boller.
Hypertension and risk of dementia in the elderly.
Am J Med, 90 (1991), pp. 14-19
[18.]
L. Kilander, H. Nyman, M. Boberg, L. Hanssson, H. Lithell.
Hypertension is related to cognitive impairment. A 20-year-follow-up of 999 men.
Hypertension, 31 (1998), pp. 780-786
[19.]
J.R. Banegas, F. Rodríguez-Artalejo, J.J. De la Cruz Troca, P. Guallar-Castillón, J. Del Rey Calero.
Blood pressure in Spain. Distribution, awareness, control, and benefits of a reduction in average pressure.
Hypertension, 32 (1998), pp. 998-1002
[20.]
T. Sáez, C. Suárez, F. Blanco, R. Gabriel.
Epidemiología de las enfermedades cardiovasculares en la población anciana española.
Rev Esp Cardiol, 51 (1998), pp. 864-873
[21.]
W.B. Stason.
Economic impact of blood pressure.
Hypertension primer, pp. 286-288
[22.]
H. Pardell, R. Tresserras, P. Armario, R. Hernández.
La hypertension arterial desde la perspectiva económica.
Investigación en hipertensión arterial. Temas de Actualidad, pp. 199-216
[23.]
F.S. Collins.
Shattuck Lecture - Medical and societal consequences of the human genome project.
N Engl J Med, 341 (1999), pp. 28-37
[24.]
S.T. Turner, G.L. Schwartz, A.B. Chapman, W.D. Hall, E. Boerwinkle.
Antihypertensive pharmacogenetics: getting the right drug into the right patient.
J Hypertens, 19 (2001), pp. 1-11
[25.]
P. Ferrari.
Pharmacogenomics: a new approach to individual therapy of hypertension?.
Curr Opin Nephrol Hypertens, 7 (1998), pp. 217-222
[26.]
S.S. Franklin, S.A. Khan, N.D. Wong, M.G. Larson, D. Levy.
Is pulse pressure more important than systolic blood pressure in predicting coronary heart disease events?.
Circulation, 100 (1999), pp. 354-360
[27.]
P. Owens, S. Lyons, E. O’Brien.
Ambulatory blood pressure in the hypertensive population: patterns and prevalence of hypertensive subforms.
J Hypertens, 16 (1998), pp. 1735-1743
[28.]
J.N. Cohn.
Arteries, myocardium, blood pressure and cardiovascular risk: towards a revised definition of hypertension.
J Hypertens, 16 (1998), pp. 2117-2124
[29.]
J. Díez, C. Laviades.
Monitoring fibrillar collagen turnover in hypertensive heart disease.
Cardiovasc Res, 35 (1997), pp. 202-205
[30.]
R. Bigazzi, S. Bianchi, D. Baldari, V.M. Campese.
Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension.
J Hypertens, 16 (1998), pp. 1325-1333
[31.]
P.M. Ridker.
Evaluating novel cardiovascular risk factors: can we better predict heart attacks?.
Ann Intern Med, 130 (1999), pp. 933-937
[32.]
J. Muntwyler, T.F. Lüscher.
Assessment of cardiovascular risk: time to apply genetic risk factors?.
Eur Heart J, 21 (2000), pp. 611-613
[33.]
W.B. Kannel.
Risk stratification in hypertension: new insights from the Framingham study.
Am J Hypertens, 13 (2000), pp. 3-10
[34.]
C. Lenfant, E.J. Roccella.
A call to action for more aggressive treatment of hypertension.
J Hypertens, 17 (1999), pp. 3-7
[35.]
L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, et al.
Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
Lancet, 351 (1998), pp. 1755-1762
[36.]
L.R. Krakoff.
Hypertension specialists: ready or not, here we come.
Am J Hypertens, 12 (1999), pp. 242-243
[37.]
C. Lenfant.
Training the next generation of biomedical researchers. Challenges and opportunities.
Circulation, 102 (2000), pp. 368-370
[38.]
L.D. Swales.
Evidence-based medicine and hypertension.
J Hypertens, 17 (1999), pp. 1511-1516
[39.]
Joint National Committee. The Sixth Report of the Joint National Committe on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med, 157 (1997), pp. 2413-2445
[40.]
Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension.
J Hypertens, 17 (1999), pp. 151-183
[41.]
P. Rodríguez Pérez, P. Hernando.
Epidemiología del envejecimiento español.
Nefrología, 17 (1997), pp. 9-14
Copyright © 2001. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.